Phase 1b trial of pembrolizumab monotherapy for relapsed/refractory multiple myeloma: KEYNOTE-013

Br J Haematol. 2019 Aug;186(3):e41-e44. doi: 10.1111/bjh.15888. Epub 2019 Apr 1.
No abstract available

Keywords: PD-1 (PDCD1); multiple myeloma; pembrolizumab.

Publication types

  • Clinical Trial, Phase I
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Antineoplastic Agents, Immunological / therapeutic use*
  • Cohort Studies
  • Female
  • Humans
  • Male
  • Multiple Myeloma / drug therapy*
  • Multiple Myeloma / mortality
  • Recurrence
  • Survival Analysis

Substances

  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents, Immunological
  • pembrolizumab

Associated data

  • ClinicalTrials.gov/NCT01953692